{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapy+and+antibodies&page=3", "query": { "intervention": "Chemotherapy and antibodies", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 1715, "total_pages": 172, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapy+and+antibodies&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapy+and+antibodies&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T08:05:56.738Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06264180", "title": "VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Melanoma" ], "interventions": [ { "name": "Vusolimogene Oderparepvec", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab + Relatlimab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Single-agent chemotherapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Replimune, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 400, "start_date": "2024-07-11", "completion_date": "2031-03-31", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-09T08:05:56.738Z", "location_count": 50, "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 42 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06264180" }, { "nct_id": "NCT02327169", "title": "A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Nonhematologic Malignancies" ], "interventions": [ { "name": "MLN2480", "type": "DRUG" }, { "name": "MLN0128", "type": "DRUG" }, { "name": "Alisertib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2015-01-14", "completion_date": "2018-07-02", "has_results": true, "last_update_posted_date": "2020-02-25", "last_synced_at": "2026-10-09T08:05:56.738Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02327169" }, { "nct_id": "NCT00460603", "title": "Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "bevacizumab", "type": "DRUG" }, { "name": "AG-013726", "type": "DRUG" }, { "name": "AG-013736 (axitinib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 187, "start_date": "2006-01", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2013-12-06", "last_synced_at": "2026-10-09T08:05:56.738Z", "location_count": 106, "location_summary": "Daphne, Alabama • Huntsville, Alabama • Mobile, Alabama + 83 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Antioch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00460603" }, { "nct_id": "NCT07007559", "title": "ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer, Metastatic" ], "interventions": [ { "name": "Evorpacept (ALX148)", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ALX Oncology Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2025-12-10", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-09T08:05:56.738Z", "location_count": 28, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07007559" }, { "nct_id": "NCT03816345", "title": "Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Autoimmune Disease", "Crohn Disease", "Dermatomyositis", "Hematopoietic and Lymphoid Cell Neoplasm", "Inflammatory Bowel Disease", "Malignant Solid Neoplasm", "Multiple Sclerosis", "Psoriasis", "Psoriatic Arthritis", "Rheumatoid Arthritis", "Sjogren Syndrome", "Systemic Lupus Erythematosus", "Systemic Scleroderma", "Ulcerative Colitis" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Fluoropyrimidine", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Platinum Compound", "type": "DRUG" }, { "name": "Platinum Doublet", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2019-07-16", "completion_date": "2028-03-30", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-09T08:05:56.738Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Palo Alto, California • Sacramento, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03816345" }, { "nct_id": "NCT03593902", "title": "Cardiac Safe Transplants for Systemic Sclerosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Systemic Sclerosis", "Scleroderma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "rATG", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "IVIg", "type": "BIOLOGICAL" }, { "name": "Autologous Stem Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 9, "start_date": "2018-05-17", "completion_date": "2019-10-09", "has_results": true, "last_update_posted_date": "2020-08-12", "last_synced_at": "2026-10-09T08:05:56.738Z", "location_count": 2, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03593902" }, { "nct_id": "NCT06435429", "title": "A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic HER2-positive Breast Cancer" ], "interventions": [ { "name": "Zanidatamab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 550, "start_date": "2024-08-13", "completion_date": "2030-10-18", "has_results": false, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-10-09T08:05:56.738Z", "location_count": 48, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Cerritos, California + 34 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06435429" }, { "nct_id": "NCT01399372", "title": "Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chemotherapeutic Agent Toxicity", "Cognitive/Functional Effects", "Lymphoma", "Neurotoxicity", "Radiation Toxicity" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Procarbazine", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "low-dose whole-brain radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2011-09", "completion_date": "2022-05-20", "has_results": true, "last_update_posted_date": "2023-07-20", "last_synced_at": "2026-10-09T08:05:56.738Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01399372" }, { "nct_id": "NCT03719105", "title": "Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "NK-Cell Lymphoma", "NK-Cell Leukemia", "Peripheral T Cell Lymphoma" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "pralatraxate,", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "calaspargase pegol", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Brentuximab Vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York Medical College", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "31 Years", "sex": "ALL", "summary": "1 Year to 31 Years" }, "enrollment_count": 40, "start_date": "2019-03-01", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-09T08:05:56.738Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03719105" }, { "nct_id": "NCT00849745", "title": "Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Lupus Erythematosus", "Systemic Sclerosis" ], "interventions": [ { "name": "Nonmyeloablative allogeneic stem cell transplant", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 4, "start_date": "2003-01", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2016-06-23", "last_synced_at": "2026-10-09T08:05:56.738Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00849745" } ] }